Yes

I have received consultancy fees from WHO for conduct of systematic reviews relating to treatment of tuberculosis Since 2020 I have been an academic partner in the UNITE4TB consortium, a new public-private partnership funded by the European Union Innovative Medicines Initiative and the European Federation of Pharmaceutical Industries until 2028. However, though this role involves engagement with industrial partners (GSK, Janssen, Evotech) in pre-competitive areas of research into TB drug development, these activities are fully supported by public funding from the EU and neither myself nor my research institution receive any funding from EFPIA or from the individual industrial partners. From June 2019-June 2023 I was a co-investigator on a grant from ViiV Healthcare focusing on drug interactions between higher dose rifampicin and dolutegravir. However, I received no personal, salary or other financial benefits from this grant. I have attended expert advisory meetings relating to TB drug development convened by GSK and Janssen for which I received no payment or benefit (honorarium, expenses, hospitality)

No

No

No